Health Enhancement Products Appoints Dr. John D. Crissman to Its Board of Directors

SCOTTSDALE, AZ--(Marketwire - October 19, 2010) -  Health Enhancement Products, Inc. (OTCBB: HEPI) announced today that Dr. John D. Crissman has been named to its Board of Directors.

John D. Crissman, MD, served as Dean of Wayne State University's School of Medicine in Detroit, Michigan, from June 1999 to October 2004. During this same period, he also held the positions of President, Academic Health Center Services and Senior Vice President of Medical Affairs at the Detroit Medical Center. From 1990 to June 1999, Dr. Crissman served as Chair of Pathology of Wayne State University's School of Medicine, and Specialist-in-Chief, Pathology and Laboratory Service, at the Detroit Medical Center. He serves as a Director at the Detroit Medical Center. He served as an Independent Director of Caraco Pharmaceutical Laboratories Ltd. from July 20, 2005 to October 7, 2009. Dr. Crissman serves as a tenured professor in the Department of Pathology. He received a Bachelor of Science degree from the Massachusetts Institute of Technology in Cambridge, Massachusetts and his Doctor of Medicine degree from Western Reserve University in Cleveland, Ohio.

"We're thrilled to have attracted someone with Dr. Crissman's background," commented, John Gorman, a Director and fellow board member. "Dr. Crissman has spent his professional life as a scientist and science administrator; he has also served on numerous NIH review committees. He brings to HEPI extensive experience in the evaluation and administration of science as it relates to human health and disease. He adds, once again, more experience and insight to HEPI's Board. Dr. Crissman fits right into the strategic shifts that HEPI is implementing to better position our company for future growth."

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTCBB: HEPI) is a health & wellness company engaged in the development of products comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme® (PAZ™) a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme®.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

For more information, please visit http://www.heponline.com.

Contact Information:

IR Contact:
David Sasso
954.907.8987